PRESS RELEASE
News
-
-
PRESS RELEASE
ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
Rosen Law Firm urges AlloVir, Inc. investors with losses during Mar 22, 2022 - Dec 21, 2023, to seek counsel before Mar 19, 2024, for securities class action (NASDAQ: ALVR). Details indicate false and misleading statements made by AlloVir -
-
-
PRESS RELEASE
AMA Chicago's BrandSmart 2024 to Explore the 'Future of Brands in an Experience-Driven Economy' During 22nd Annual Conference in Chicago
Top talent in the marketing and branding industry will gather at the AON Grand Ballroom at Navy Pier in Chicago on Thursday, April 25, 2024, for BrandSmart 2024. The conference will feature renowned speakers and industry expert panels uncovering actionable strategies to empower brands in the ever-evolving market -
PRESS RELEASE
stUSDT 2023 Year in Review
The press release announces the 2023 Year in Review for stUSDT, the first Real-World Asset (RWA) product in the TRON ecosystem. It highlights the platform's features, growth, key events, and future commitment. Disclaimer: stUSDT and related services are not available to users in the United States -
PRESS RELEASE
ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
Rosen Law Firm encourages BioNTech SE investors to secure counsel before important deadline in securities class action. Investors may be entitled to compensation. A class action lawsuit has been filed -
PRESS RELEASE
Bellevue expects a sharp drop in consolidated net profit to CHF 15 mn – ordinary dividend of CHF 1.15 per share to be proposed
Bellevue Group AG expects a sharp drop in consolidated net profit to CHF 15 mn for 2023. Dividend proposal of CHF 1.15 per share reiterated, with a shareholder-friendly dividend policy. Ad hoc announcement pursuant to Art. 53 of the SWX Listing Rules -
PRESS RELEASE
MeVis publishes figures for financial year 2022/2023 and forecast for 2023/2024
MeVis Medical Solutions AG announces financial results for 2022/2023 with turnover down to €17.3 million and forecast for 2023/2024 with expected slight sales increase and stable EBIT. Details on sales, EBIT, and earnings provided -
